Interferonalpha

INF-a was first reported in 1984 by Bunn et al. for the treatment of advanced and heavily pretreated MF/SS, with an overall response rate of 45%.52 Papa et al. showed response rates between 70% for advanced stage III-IV and 80% for early stage patch/plaque disease.53 Olsen et al. showed, in an investigational trial of 3 versus 36 MU daily of INF a-2a in 22 patients with clinical stage I-IV MF/SS, an overall response rate of 38% in low-dose-treated patients compared to 79% in high-dose-treated patients.54 Side effects were dose related and were most commonly flu-like symptoms. The development of neutralizing antibodies has been associated with INF-a therapy, with variable impact on response rates.55 They appear to be higher in patients treated with INF a-2a compared to INF a-2b. The combination therapy IFN-a and PUVA resulted in high response rates in more than 90% of patients and showed superiority to other combinations.5657

0 0

Post a comment